DUBLIN–(BUSINESS WIRE)–The “Global
Progressive Supranuclear Palsy Therapeutics Market 2019-2023”
report has been added to ResearchAndMarkets.com’s
offering.
The progressive supranuclear palsy therapeutics market will register a
CAGR of nearly 5% by 2023.
The increasing strategic alliances are expected to trigger the
progressive supranuclear palsy therapeutics market growth during the
forecast period.
Vendors in the market are entering into strategic alliances for
co-developing and co-commercializing drugs of for licensing the drugs to
large pharmaceutical vendors including the academic institutions and
several small pharmaceutical vendors lacking the advanced manufacturing
processes.
Increasing strategic alliances
The increasing strategic alliances are likely to result in the faster
completion of the study leading to the quicker approval of the
therapies, thus resulting in the growth of the global progressive
supranuclear palsy therapeutics market during the forecast period.
Adverse side effects
The presence of strong adverse side effects of these drugs is currently
a major challenge acting as a barrier to the market growth and is
expected to remain a challenge to the growth of the global progressive
supranuclear palsy therapeutics market during the forecast period.
Competitive Landscape
The market appears to be highly concentrated. This market research
report will help clients identify new growth opportunities and design
unique growth strategies by providing a comprehensive analysis of the
market’s competitive landscape and offering information on the products
offered by companies.
Key Players
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Biogen Inc.
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
- Dopamine – Market size and forecast 2018-2023
- Anticholinergic agents – Market size and forecast 2018-2023
- Tricyclic antidepressants – Market size and forecast 2018-2023
- Others – Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- RoW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Biogen Inc.
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
For more information about this report visit https://www.researchandmarkets.com/r/yrda0z
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900